Your browser doesn't support javascript.
loading
Increased hepatic glucagon sensitivity in totally pancreatectomised patients.
Rix, Iben; Lund, Asger B; Garvey, Lars F; Hansen, Carsten P; Chabanova, Elizaveta; Hartmann, Bolette; Holst, Jens J; Vilsbøll, Tina; Van Hall, Gerrit; Knop, Filip K.
Afiliação
  • Rix I; Center for Clinical Metabolic Research, Copenhagen University Hospital - Herlev and Gentofte, 2900 Hellerup, Denmark.
  • Lund AB; Medical & Science, Zealand Pharma A/S, 2860 Søborg, Denmark.
  • Garvey LF; Center for Clinical Metabolic Research, Copenhagen University Hospital - Herlev and Gentofte, 2900 Hellerup, Denmark.
  • Hansen CP; Clinical Research, Steno Diabetes Center Copenhagen, 2730 Herlev, Denmark.
  • Chabanova E; Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, 2200 Copenhagen, Denmark.
  • Hartmann B; Center for Clinical Metabolic Research, Copenhagen University Hospital - Herlev and Gentofte, 2900 Hellerup, Denmark.
  • Holst JJ; Department of Surgery, Copenhagen University Hospital - Rigshospitalet, 2100 Copenhagen, Denmark.
  • Vilsbøll T; Department of Radiology, Copenhagen University Hospital - Herlev and Gentofte, 2730 Herlev, Denmark.
  • Van Hall G; Department of Biomedical Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, 2200 Copenhagen, Denmark.
  • Knop FK; Novo Nordisk Foundation Center for Basic Metabolic Research, Faculty of Health and Medical Sciences, University of Copenhagen, 2200 Copenhagen, Denmark.
Eur J Endocrinol ; 190(6): 446-457, 2024 Jun 05.
Article em En | MEDLINE | ID: mdl-38781444
ABSTRACT

OBJECTIVE:

The metabolic phenotype of totally pancreatectomised patients includes hyperaminoacidaemia and predisposition to hypoglycaemia and hepatic lipid accumulation. We aimed to investigate whether the loss of pancreatic glucagon may be responsible for these changes.

METHODS:

Nine middle-aged, normal-weight totally pancreatectomised patients, nine patients with type 1 diabetes (C-peptide negative), and nine matched controls underwent two separate experimental days, each involving a 150-min intravenous infusion of glucagon (4 ng/kg/min) or placebo (saline) under fasting conditions while any basal insulin treatment was continued.

RESULTS:

Glucagon infusion increased plasma glucagon to similar high physiological levels in all groups. The infusion increased hepatic glucose production and decreased plasma concentration of most amino acids in all groups, with more pronounced effects in the totally pancreatectomised patients compared with the other groups. Glucagon infusion diminished fatty acid re-esterification and tended to decrease plasma concentrations of fatty acids in the totally pancreatectomised patients but not in the type 1 diabetes patients.

CONCLUSION:

Totally pancreatectomised patients were characterised by increased sensitivity to exogenous glucagon at the level of hepatic glucose, amino acid, and lipid metabolism, suggesting that the metabolic disturbances characterising these patients may be rooted in perturbed hepatic processes normally controlled by pancreatic glucagon.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Pancreatectomia / Glucagon / Diabetes Mellitus Tipo 1 / Fígado Limite: Adult / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Pancreatectomia / Glucagon / Diabetes Mellitus Tipo 1 / Fígado Limite: Adult / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2024 Tipo de documento: Article